Targeted Solid Tumor NGS Fusion Panel
Also known as: Targeted Solid Tumor Fusion Panel
Use
This RNA‑based next‑generation sequencing panel is intended for detection of translocations and gene fusions in solid tumors involving both known and novel fusion partners. It targets key actionable and clinically relevant genes such as ALK, BRAF, FGFR family, MET (including exon 14 skipping), NOTCH1/2, NRG1, NTRK1/2/3, PDGFB, PDGFRA, PDGFRB, RAF1, RET, and ROS1.
Special Instructions
Requires FFPE tissue; paraffin block preferred. Alternatively, send 1 H&E slide plus 5‑10 unstained slides (≥5 µm), using positively‑charged slides and 10% NBF fixative; zinc fixatives must not be used. Use cold pack for transport without direct contact with specimen. For New York State clients, date and time of collection must be provided.
Limitations
Not provided.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
21 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Paraffin block preferred; or 1 H&E slide plus 5‑10 unstained slides ≥5 µm on positively‑charged slides with 10% NBF fixation; do not use zinc fixatives.